Skip to content
DataLookout
Menu

NCT07891182

VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Intraocular pressure
Timeframe: Postoperative day 1, week 1, month 1, month 2, and month 3

Secondary (4)

Surgical failure
Medication Burden
Hypertensive phase
Treatment adverse events and serious treatment adverse events

Arms and interventions

Ahmed Tube Surgery with Aflibercept Intravitreal Injection GroupExperimental

Participants will undergo standard of care Ahmed tube surgery and will receive one 8 mg injection of intravitreal aflibercept at three timepoints in the study: at the conclusion of surgery, Postoperative Month 1, Postoperative Month 2. Total duration of participation in this arm is 6 months

Ahmed Tube Surgery without Perioperative Aflibercept (Control Group)Active comparator

Participants will undergo standard of care Ahmed tube surgery without any injections of intravitreal aflibercept. Total duration of participation in this arm is 6 months.

Drugs: Aflibercept Injection

Procedures: Ahmed Tube Surgery

Sites

1 site in 1 country

  • Bascom Palmer Eye InstituteMiami, Florida, United States